TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27869715
Drug: Inositol-stabilized arginine
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol-stabilized arginine silicate (ASI; Nitrosigine®) 1500 mg/day for a 10-min period
Study: 12140664
Drug: Flupirtine 100
Normalized name: flupirtine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine 100 mg
Study: 22940462
Drug: Daily anger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily anger expression in LBP patients
Study: 15776331
Drug: CHO (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (10% glucose, 30 mmol . l (‐1) NaCl)
Study: 15776331
Drug: W (water,
Approvals — FDA: no, EMA: no, PMDA: no
Description: W (water, 30 mmol . l (‐1) NaCl)
Study: 19563665
Drug: Rectal diazepam
Normalized name: diazepam Rectal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diazepam
Study: 1781807
Drug: Cefadroxil plus
Normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefadroxil plus N-acetylcysteine (1000 mg cefadroxil + 200 mg N-acetylcysteine)
Study: 1781807
Drug: Cefadroxil alone
Normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefadroxil alone (1000 mg)
Study: 6982626
Drug: Thiopentone (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (3.0 mg/kg)
Study: 6982626
Drug: Althesin (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Althesin (0.07 ml/kg)
Study: 7125264
Drug: Ketamine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1.5 mg/kg)
Study: 6982626
Drug: Fentanyl (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.01 mg/kg) added to Althesin and Flunitrazepam
Study: 6982626
Drug: Fentanyl (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.01 mg/kg) added to Ketamine
Study: 29652795
Drug: Non-nucleoside reverse
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Study: 31629649
Drug: Control (repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (repeated initial vaccination with HBVaxPro 10 μg or Engerix‐B 20 μg)
Study: 31629649
Drug: HBVaxPro 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBVaxPro 40 μg
Study: 22886490
Drug: Autologous pulsed
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous pulsed dendritic cell vaccine
Study: 8737755
Drug: Intravenous Erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Erythropoietin (IV EPO)
Study: 8737755
Drug: Subcutaneous Erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Erythropoietin (SC EPO)
Study: 1351025
Drug: Bisoprolol 5
Normalized name: bisoprolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 5 mg once a day
Study: 1351025
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg a day (50 mg twice a day)
Study: 6741192
Drug: Daily perseverance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily perseverance training of 60 min at about 50% VO2 max
Study: 21102473
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) treatment for a mean duration of 1 year
Study: 21102473
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment or vitamin E
Study: 16485727
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) treatment
Study: 19920081
Drug: Patient intervention
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient intervention (20 weekly group sessions followed by 12 monthly telephone counseling contacts focusing on weight loss, DASH dietary pattern, exercise, and reduced sodium intake)
Study: 25970229
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 0.6 mg/kg with additional doses of 10-20 mg until OAA/S score 2-4
Study: 8596489
Drug: Trelan G‐75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trelan G‐75 (1,200 mOsm/L, 225 mL) equivalent to 75 g glucose
Study: 16440531
Drug: Rupatadine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 10 mg once daily
Study: 29547159
Drug: Pyridoxine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine (30 mg/kg/day) with oral prednisolone (4 mg/kg/day)
Study: 29547159
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (4 mg/kg/day) alone
Study: 22985607
Drug: Phlebotomy (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebotomy (450 mL, every 2 weeks until serum ferritin levels of 20 ng/mL)
Study: 17922939
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) group treatment
Study: 10332014
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment (24 sessions of 15 minutes, frequency 0.89 MHz, intensity 2.5 W/cm², pulsed mode 1:4)
Study: 30634204
Drug: Rhubarb (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb (80 mg/kg, twice per day) combined with medicinal activated carbon (1.5 g each time, thrice per day) for 8 weeks
Study: 30634204
Drug: Medicinal activated
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicinal activated carbon (1.5 g each time, thrice per day) for 8 weeks
Study: 21074974
Drug: Supportive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive Therapy
Study: 17884442
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg extract of green and black tea per day for 3 months
Study: 12053829
Drug: Prevention and
Normalized name: PINE NEEDLE OIL (PINUS MUGO) 5 mg in 100 mL TOPICAL LIQUID [JEUNCELL Hair Loss Prevention and Hair Growth Tonic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prevention and treatment strategies for traveller's diarrhoea
Study: 9455509
Drug: Topical paromomycin/MBCL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical paromomycin/MBCL plus injectable Sb for 7 days
Study: 7658950
Drug: Drink with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink with 6% carbohydrates and 0 mmol.l‐1 Na+
Study: 7658950
Drug: Drink with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink with 6% carbohydrates and 8.8 mmol.l‐1 Na+
Study: 7658950
Drug: Drink with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink with 6% carbohydrates and 18.5 mmol.l‐1 Na+
Study: 3967455
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg amantadine
Study: 16794570
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg amantadine
Study: 16794570
Drug: Amantadine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (50 mg and 100 mg)
Study: 8809929
Drug: Exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise program (twice a week for 8 weeks)
Study: 7941802
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose 5% plus electrolytes, neostigmine, and dexpanthenon (Group A)
Study: 7941802
Drug: Standardized commercially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized commercially available solutions without intravenous stimulation of the bowel (Group B)
Study: 30961913
Drug: Recruitment manoeuvres
Normalized name: Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recruitment manoeuvres with PEEP titration
Study: 15005472
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) using Fuji IX GP and Ketac‐Molar Aplicap in Class II cavities
Study: 15005472
Drug: Conventional cavity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cavity preparation using Fuji IX GP and Ketac‐Molar Aplicap in Class II cavities
Study: 15005472
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) using Fuji IX GP and Ketac‐Molar Aplicap in Class I cavities
Study: 3062082
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 250 mg/day
Study: 3062082
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 500 mg/day
Study: 3062082
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 750 mg/day
Study: 26399865
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (50,000 IUs thrice weekly for 8 weeks and 50,000 IU every other week for 8 weeks)
Study: 19586799
Drug: Simvastatin/Ezetimibe 40/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin/Ezetimibe 40/10 mg daily
Study: 15152874
Drug: Cefditoren twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefditoren twice a day for 10 days
Study: 15152874
Drug: Cefuroxim twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxim twice a day for 10 days
Study: 9848851
Drug: N-methyl-D-aspartate receptor
Normalized name: N-methyl-D-aspartate receptor antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-methyl-D-aspartate receptor antagonist Selfotel
Study: 19756416
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate (1500 mg/day) + omega-3 fatty acids (EPA and DHA)
Study: 15253739
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (300 mg, intravenous sodium ascorbate)
Study: 2881320
Drug: 0.02 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mcg/kg CCK‐8
Study: 2881320
Drug: 0.04 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mcg/kg CCK‐8
Study: 22652582
Drug: PCV7 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV7 (1.0 mL)
Study: 16002808
Drug: Phosphatidylcholine supplementation
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylcholine supplementation (2.6 g choline/d)
Study: 16002808
Drug: Phosphatidylcholine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylcholine (1.5 g choline) on the first day of supplementation
Study: 8554943
Drug: Pancopride 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancopride 10 mg
Study: 8554943
Drug: Pancopride 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancopride 5 mg
Study: 1782064
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of 20 mg/m2 per day on days 1‐5 and 22‐26 with irradiation on days 2, 5, 9, 16, 23 and 26
Study: 1782064
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg cisplatin over 24 h commencing 1 h before each fraction of irradiation on days 1, 4, 8, 11, 15 and 18
Study: 21909502
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral squamous cell carcinoma patients
Study: 21909502
Drug: Postoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative oral squamous cell carcinoma patients
Study: 21909502
Drug: Oral squamous
Normalized name: Vespula squamosa venom protein
DrugBank: Vespula squamosa venom protein (DB11032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral squamous cell carcinoma patients (both groups)
Study: 2666532
Drug: Oral steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroid CME treatment
Study: 16548360
Drug: Biqi capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biqi capsule (BC)
Study: 10769442
Drug: Dacron patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacron patch
Study: 8842602
Drug: Buccal GLP-I
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal GLP-I tablet (119 nmol)
Study: 6360325
Drug: 5-fluorouracil and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil and methyl-CCNU administered in combination, given in discrete 5-day courses at 7-week intervals.
Study: 27548104
Drug: Lenvatinib (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib (24 mg once daily)
Study: 15791501
Drug: Clodronate 400
Normalized name: clodronic acid 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 400 mg; 1200 mg/day (p.o.)
Study: 2937673
Drug: Sicorten cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sicorten cream
Study: 2937673
Drug: Sicorten ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sicorten ointment
Study: 18715405
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of cetrorelix (4-7 days)
Study: 12859157
Drug: Alternating therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating therapy (regimen C)
Study: 10368202
Drug: Topical vasoactive
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vasoactive cream (aminophylline, isosorbide dinitrate, co-dergocrine mesylate)
Study: 10368202
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (no pharmacologically active ingredients)
Study: 1997243
Drug: Repair and
Normalized name: Pantene Repair And Protect Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repair and augmentation of the ACL with an iliotibial strip
Study: 31451579
Drug: Clobazam (GABAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (GABAA modulator)
Study: 31451579
Drug: Arbaclofen (GABAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbaclofen (GABAB modulator)
Study: 28974349
Drug: Reduced-dose ICS/LABA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose ICS/LABA
Study: 26489028
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous cyclophosphamide (CYC)
Study: 26489028
Drug: Oral mycophenolate
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mycophenolate mofetil (MMF)
Study: 17115180
Drug: Glutamine (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (0.125 g kg body mass(‐1))
Study: 31096728
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (Group G)
Study: 28272120
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Imipramine + Pregabalin)
Study: 28272120
Drug: Imipramine (monotherapy)
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine (monotherapy)
Study: 28272120
Drug: Pregabalin (monotherapy)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin (monotherapy)
Study: 15786695
Drug: Cabergoline at
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline at 0.5 mg/week orally for 4 consecutive weeks
Study: 8005305
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (Control group)
Study: 17244442
Drug: Intraocular injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraocular injections of steroids and anti-vascular endothelial growth factor agents
Study: 17244442
Drug: Sustained drug
Normalized name: Sustain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained drug release devices
Study: 22032832
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (21 mg)
Study: 6216427
Drug: Locoid scalp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoid scalp lotion
Study: 31502856
Drug: Laser Acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser Acupuncture (LA), administered at traditional Chinese acu-points on the affected side, once a day, 5 times a week, for 4 weeks (N=43)
Study: 31502856
Drug: Placebo Laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Laser Acupuncture (placebo LA), administered using the same device and protocol, with the LA device switched off (N=41)
Study: 19643944
Drug: Weekly, supervised,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly, supervised, outpatient‐based exercise plus unsupervised home exercise
Study: 12182992
Drug: Diphenoxylate and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenoxylate and atropine orally, 2.5 mg four times daily (n = 28)
Study: 12182992
Drug: Octreotide s.c.,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide s.c., 100 microg three times daily (n = 33)
Study: 20976161
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (3.2 g EPA and 2.0 g DHA)
Study: 20976161
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Montelukast + Fish oil)
Study: 20976161
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil and Combination treatment
Study: 11963645
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Dilavenil)
Study: 9811158
Drug: Mibefradil 50
Normalized name: mibefradil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil 50 mg once daily for 8 days
Study: 9811158
Drug: Mibefradil 100
Normalized name: mibefradil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil 100 mg once daily for 8 days
Study: 9811158
Drug: Mibefradil 150
Normalized name: mibefradil
DrugBank: Mibefradil (DB01388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mibefradil 150 mg once daily for 8 days
Study: 9811158
Drug: Mibefradil 200
Normalized name: mibefradil
DrugBank: Mibefradil (DB01388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mibefradil 200 mg once daily for 8 days
Study: 9811158
Drug: Mibefradil 40
Normalized name: mibefradil
DrugBank: Mibefradil (DB01388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mibefradil 40 mg intravenous dose
Study: 2522756
Drug: Organoclay preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organoclay preparation
Study: 12441211
Drug: lacidipine 2
Normalized name: lacidipine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lacidipine 2 mg/day
Study: 1906692
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg rt-PA
Study: 1906692
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg rt-PA
Study: 7723950
Drug: rt-PA (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA (150 mg or 100 mg)
Study: 6779303
Drug: Chlormethiazole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormethiazole (1 g at bedtime and 0.5 g early the following morning)
Study: 23684138
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin (500 mg) 1 hour before procedure (Group 2, n = 141)
Study: 23684138
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of fosfomycin tromethamine (FT) approximately 12 hours before procedure (Group 3, n = 137)
Study: 12140392
Drug: Losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan potassium (50 mg)
Study: 30659024
Drug: Osimertinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib (80 mg orally, once daily)
Study: 29743071
Drug: First-line coil
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line coil treatment
Study: 19213339
Drug: CT‐F (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT‐F (chemotherapy with FOLFOX protocol)
Study: 15908833
Drug: Clinic-administered, abstinence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic-administered, abstinence-based incentive program; parent-directed contingency management; clinic-administered incentive program for parent participation; individual cognitive-behavioral therapy
Study: 6337742
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (40 mg orally)
Study: 22984818
Drug: Bladder filling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder filling with normal saline prior to trial of void (up to 500 mL or first sensation of fullness)
Study: 17686555
Drug: HCV peptide-vaccine
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV peptide-vaccine IC41
Study: 7942475
Drug: Intracoronary phentolamine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary phentolamine, 2 mg, infused regionally through the balloon catheter before coronary artery angioplasty (n=12)
Study: 2894161
Drug: rilmenidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilmenidine (0.5 mg)
Study: 2894161
Drug: rilmenidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilmenidine (1 mg)
Study: 2894161
Drug: rilmenidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilmenidine (2 mg)
Study: 26286147
Drug: Qing-Feng-Gan-Ke Granules
Normalized name: qing feng teng stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qing-Feng-Gan-Ke Granules (QFGKG) 12.0 g twice daily
Study: 26286147
Drug: Placebo 12.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 12.0 g twice daily
Study: 22729212
Drug: High-dose NRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose NRT (31.2 mg for the first 4 weeks, then 20.8 mg for 4 weeks)